Press Releases

Press Releases

Nov 07, 2019
NanoFlu pivotal Phase 3 clinical trial initiated October 2019 with top-line data expected in the first quarter of 2020 Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company...
Sep 19, 2019
GAITHERSBURG, Md. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck , President and Chief Executive Officer, will present at the Ladenburg...
Aug 07, 2019
Agreement with the FDA on Phase 3 non-inferiority immunogenicity study design for NanoFlu™ NanoFlu pivotal Phase 3 clinical trial expected to initiate in the third quarter of 2019 with top-line data in the first quarter of 2020 Strategic partnership completed with Catalent ; raised $18 million...
Displaying 1 - 10 of 26